Guest: Mohamad Bydon, M.D.
Host: Jeffrey S. Brault, D.O. (<a href='https://twitter.com/JeffBrault'>@JeffBrault</a>)
Dr. Mohamad Bydon discusses harnessing autologous, adipose-derived, mesenchymal stem cells to treat blunt traumatic spinal cord injuries. He details how the the ground-breaking clinical trial is setup, the safety and efficacy goals of the current study, and what they hope to do in phase two.
Connect with the Mayo Clinic’s PM&R Department on Twitter <a href='https://twitter.com/MayoClinicPMR'>@MayoClinicPMR</a>.
Deeper Dive: 
<ul><li>CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue–Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury: <a href='https://doi.org/10.1016/j.mayocp.2019.10.008'>https://doi.org/10.1016/j.mayocp.2019.10.008</a></li>
<li>To learn more about Mayo Clinic’s Neuroinformatics Lab visit here: <a href='https://www.mayo.edu/research/labs/neuro-informatics/about'>https://www.mayo.edu/research/labs/neuro-informatics/about</a></li>
<li>For inquiries regarding the study email: <a href='mailto:neuroinformatics@mayo.edu'>neuroinformatics@mayo.edu</a></li>
</ul>

Opioid Edition 2: Managing Acute and Chronic Pain

Stay on top of your practice with podcasts from Mayo Clinic. Concise, relevant conversations with Mayo Clinic Physical Medicine and Rehabilitation experts. Working to add quality back to life.